Regencell Bioscience
RGC
Market cap $781M

60.00 USD

+28.40

89.87%

At close Apr 30, 4:00 PM EDT

After hours

58.12

-1.88

3.13%

1 day

89.87%

5 days

99.40%

1 month

88.21%

3 months

1,487.30%

6 months

768.31%

Year to date

1,144.81%

1 year

1,038.52%

5 years

471.43%

10 years

471.43%

About: Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.

Employees: 12

Healthcare Drug Manufacturers - Specialty & Generic

0

Funds holding %

of 7,425 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

55% more capital invested

Capital invested by funds: $100K [Q3] → $156K (+$55.4K) [Q4]

50% more funds holding

Funds holding: 2 [Q3] → 3 (+1) [Q4]

0.1% more ownership

Funds ownership: 0.14% [Q3] → 0.24% (+0.1%) [Q4]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for RGC.

See Analyst Rankings

Financial journalist opinion

What Is Going on With Regencell Bioscience (RGC) Stock Today?

Little-known drug manufacturer Regencell Bioscience (NASDAQ: RGC ) saw its shares skyrocket on Tuesday on no apparent catalyst. However, it's possible that the exceptionally distinct business profile — specializing in traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders — caught the attention of speculators.

What Is Going on With Regencell Bioscience (RGC) Stock Today?

See News Rankings

Charts implemented using Lightweight Charts™